Yolo Akili

EndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17

Retrieved on: 
Monday, December 18, 2023
Software, General Health, Health, FDA, Health Technology, Technology, Other Technology, Other Health, Food, Ageing, Patient, Attention deficit hyperactivity disorder, ADHD, Diagnosis, Trial of the century, Endeavour, Dietary supplement, Yolo Akili

This increased age range is expected to more than double the number of pediatric patients with ADHD who are now eligible for EndeavorRx – the only FDA-authorized, game-based digital therapeutic – with a prescription from a healthcare provider.

Key Points: 
  • This increased age range is expected to more than double the number of pediatric patients with ADHD who are now eligible for EndeavorRx – the only FDA-authorized, game-based digital therapeutic – with a prescription from a healthcare provider.
  • (Akili also offers a non-prescription product for adults with ADHD, using the same technology, EndeavorOTC ™.)
  • Following treatment, participants in the study showed significant improvement on both the inattention subscale and total score of the ADHD-RS (p
  • Overall, 4 (2.5%) participants experienced a treatment-emergent adverse device event (3 decreased frustration tolerance, 1 headache; all mild or moderate).

Akili Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Mental Health, Apps, Applications, Technology, Neurology, FDA, Health Technology, Telemedicine, Virtual Medicine, Software, Biotechnology, Health, Webcast, Food, Asset, Workforce, Investment, COVID-19, Patient, ADHD, Variable, GAAP, Coronavirus, DSM-IV codes, Partnership, Total, Table, Growth, Frustration, Quality of life, Shionogi, Policy, Dietary supplement, Pharmaceutical industry, Rare-earth element, Bank, Attention, Yolo Akili

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended September 30, 2023, and provided an update on business progress.

Key Points: 
  • Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended September 30, 2023, and provided an update on business progress.
  • Total billings: Total billings, a non-GAAP financial measure defined as revenues plus the change in deferred revenue, were $699 thousand for the third quarter of 2023, compared to $170 thousand for the second quarter of 2023.
  • Non-GAAP net loss was $13.9 million for the third quarter of 2023, compared to a non-GAAP net loss of $12.6 million for the second quarter of 2023.
  • A reconciliation of the historical non-GAAP financial measures to GAAP financial measures is included in the attached financial tables.

PureTech to Present at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, PureTech Health, Clostridioides difficile infection, Schizophrenia, OTC, U.S. Department of Defense Strategy for Operating in Cyberspace, Food, KarXT, Anxiety, Fragile X-associated tremor/ataxia syndrome, Inflammation, Central nervous system, Tislelizumab, Epilepsy, IPF, KRTX, University, AML, Myenteric plexus, Ulcerative colitis, University of California, Davis, Idiopathic pulmonary fibrosis, FDA, Therapy, PRTC, Acute myeloid leukemia, LSE, Clinical trial, Bone marrow, Fast Track, Depression, New Drug Application, Head, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fibrosis, Vedanta, DSM-IV codes, CNS, Daphne, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Pharmaceutical industry, Management, Yolo Akili, FXTAS

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate in fireside chats at two upcoming investor conferences.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that members of the management team will participate in fireside chats at two upcoming investor conferences.
  • “Recently, we have been increasing our focus on our central nervous system (CNS) programs, including LYT-300 and LYT-310, that originated from our Glyph™ technology platform.
  • If approved, KarXT, invented at PureTech, will be the third therapeutic candidate to be taken from inception at PureTech to FDA regulatory approval.
  • PureTech will not move forward with the contemplated plan of merger with Gelesis and will instead focus on other strategic business initiatives.

Employees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study Finds

Retrieved on: 
Thursday, October 12, 2023
Software, Technology, Health, Diagnosis, Multimedia, Male, ADHD, Depression, Female, Emotion, Workplace, FDA, Workforce, Fear, Attention, Face, Patient, Dietary supplement, Nursing, Management, Yolo Akili

Akili engaged Wakefield Research to survey 500 employees with ADHD to better understand the experience of working with ADHD, as well as 500 managers to explore how prepared workplaces are to support employees with ADHD.

Key Points: 
  • Akili engaged Wakefield Research to survey 500 employees with ADHD to better understand the experience of working with ADHD, as well as 500 managers to explore how prepared workplaces are to support employees with ADHD.
  • (Photo: Business Wire)
    The study found that nearly all employees with ADHD (97%) think they would be capable of accomplishing more if they could better manage their symptoms.
  • Despite the many ways that ADHD can affect an employee’s success and well-being at work, care options are drastically limited.
  • When managers and employees are on the same page, it helps folks with ADHD receive the support and understanding they need.

Akili Announces Leadership Transition

Retrieved on: 
Friday, October 6, 2023
Entertainment, Mental Health, Health, Apps, Applications, Technology, Health Technology, Electronic Games, COVID-19, ADHD, Acquisition, Food, Frustration, Coronavirus, Organization, Culture, Attention deficit hyperactivity disorder predominantly inattentive, Friction, Deficit spending, Variable, FDA, Growth, Policy, Patient, Exact sciences, Regulation of tobacco by the U.S. Food and Drug Administration, Foundation Medicine, Life, DSM-IV codes, Quality of life, Management, Pharmaceutical industry, Dietary supplement, Yolo Akili

The leadership transition follows the company’s announcement in September that it plans to shift from a prescription to a non-prescription business model.

Key Points: 
  • The leadership transition follows the company’s announcement in September that it plans to shift from a prescription to a non-prescription business model.
  • “Akili’s transition to a non-prescription business is a springboard to transform the company and remove friction for the customers we serve.
  • Under his leadership, Akili realized the initial phase of its vision, introducing the world’s first and only clinically validated FDA-authorized video game treatment.
  • With his transition to the role of Board chair, Martucci replaced Palihapitiya who served as chair of the Board since investing in the company and facilitating its transition to a public listing in August 2022.

Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD

Retrieved on: 
Thursday, September 21, 2023
Technology, Mobile, Wireless, Electronic Games, Men, Health, Entertainment, Consumer, Apps, Applications, Mental Health, Medical Devices, Software, Women, Clinical Trials, Consumer Electronics, Drug, Focus, Drug Enforcement Administration, Habit, Pixel, Clinical trial, ADHD, Quality of life, Android, Attention, Attention deficit, Self-perceived quality-of-life scale, DEA, Patient, ACS, Apple, Samsung Galaxy, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Internal, Food, Mobile phone, Dietary supplement, Yolo Akili

EndeavorOTC is built on the same technology as Akili’s EndeavorRx®, the world’s first and only FDA-authorized video game treatment, for children 8-12 years old with ADHD.

Key Points: 
  • EndeavorOTC is built on the same technology as Akili’s EndeavorRx®, the world’s first and only FDA-authorized video game treatment, for children 8-12 years old with ADHD.
  • In a recent clinical trial, EndeavorOTC significantly improved focus, attention, and overall quality of life in adults struggling with ADHD symptoms.
  • “Video games are an established part of life for the majority of American adults,” said Jon David, chief product officer of Akili.
  • “By delivering an ADHD treatment via video game, we believe we’re tapping into established habits and making a clinically-proven treatment more accessible and approachable than ever before.

Akili Announces Business Transformation, Focusing on Non-prescription Model

Retrieved on: 
Wednesday, September 13, 2023
Alternative Medicine, Technology, FDA, Health, Electronic Games, Pharmaceutical, Entertainment, Mental Health, Apps, Applications, Telemedicine, Virtual Medicine, COVID-19, Workforce, Attention deficit hyperactivity disorder predominantly inattentive, Policy, Clinical trial, ADHD, Coronavirus, Quality of life, DSM-IV codes, GAAP, COVID, Variable, App Store (iOS/iPadOS), Patient, Frustration, OTC, Webcast, Growth, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Caregiver, Pharmaceutical industry, Dietary supplement, Yolo Akili

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced its strategic plan to transition from a prescription to a non-prescription business model.

Key Points: 
  • Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced its strategic plan to transition from a prescription to a non-prescription business model.
  • “Today, we are evolving our business to remove barriers for patients trying to access safe and effective non-drug treatment options,” said Eddie Martucci, CEO and co-founder of Akili.
  • Akili plans to restructure the organization around executing this new business model to reflect expected lower costs to operate a non-prescription model.
  • In connection with the restructuring, Akili will reduce staff and resources focused on its pediatric prescription business, while enabling continued support for existing pediatric customers.

PureTech Health plc – Half-Year Report

Retrieved on: 
Tuesday, August 29, 2023
Infectious Diseases, Neurology, Clinical Trials, Stem Cells, Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Clostridioides difficile infection, Plan, Central nervous system, Depression, Psychosis, University, Fragile X-associated tremor/ataxia syndrome, U.S. Department of Defense Strategy for Operating in Cyberspace, Gel, Engineering, Classification, Schizophrenia, Food allergy, Anxiety, ADHD, University of California, Davis, PureTech Health, Fast Track, Attention, CNS, Attention deficit hyperactivity disorder predominantly inattentive, AML, Investigational New Drug, Patient, Investment, KRTX, Variometer, Ageing, KarXT, FDA, IPF, Safety, Vaccine, Pharmaceutical industry, Dietary supplement, Cryptocurrency, Vedanta, Gelesis, Yolo Akili, FXTAS

Awarded up to $11.4 million from the U.S. Department of Defense to advance LYT-300 for Fragile X-associated Tremor/ Ataxia Syndrome (FXTAS).

Key Points: 
  • Awarded up to $11.4 million from the U.S. Department of Defense to advance LYT-300 for Fragile X-associated Tremor/ Ataxia Syndrome (FXTAS).
  • Akili subsequently released EndeavorOTC,10 a video game treatment to improve attention in adults 18 years and older with ADHD, available without a prescription.
  • Gelesis and PureTech have entered into an Agreement and Plan of Merger, subject to agreed upon terms and conditions.
  • PureTech has also entered into an Agreement and Plan of Merger to purchase all of the outstanding stock of Gelesis and take the company private.

Akili Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Software, Mobile, Wireless, Entertainment, Telemedicine, Virtual Medicine, Consumer Electronics, Mental Health, Apps, Applications, Technology, Health Technology, Neurology, FDA, Electronic Games, Health, Workforce, Total, Table, Attention deficit hyperactivity disorder predominantly inattentive, Prescription, COVID-19, Clinical trial, ADHD, Coronavirus, Quality of life, DSM-IV codes, GAAP, Variable, Investment, Patient, Frustration, Webcast, Growth, Ageing, Policy, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Dietary supplement, Video game, Pharmaceutical industry, Clothing, Life insurance, Bank, Yolo Akili

Prescriptions for EndeavorRx increased 27% in the second quarter of 2023 over the first quarter of 2023 and grew by 291% over the second quarter of 2022.

Key Points: 
  • Prescriptions for EndeavorRx increased 27% in the second quarter of 2023 over the first quarter of 2023 and grew by 291% over the second quarter of 2022.
  • Prescriptions for EndeavorRx were written by 1,102 unique prescribers in the second quarter of 2023, a 20% increase over the first quarter of 2023 and 130% growth over the second quarter of 2022.
  • In the second quarter of 2023, the number of new prescribers grew by 16% over the first quarter of 2023, and the number of repeat prescribers grew by 23% over the first quarter of 2023.
  • Revenues: Total revenues for the second quarter of 2023 were $114 thousand compared to $113 thousand for the first quarter of 2023.

Akili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHD

Retrieved on: 
Wednesday, June 7, 2023
Mental Health, Health, Technology, Health Technology, Software, General Health, Clinical Trials, Cognition, SSME, Depression, State University of New York Upstate Medical University, Spectrum, Policy, COVID-19, ADDA, Clinical trial, ADHD, Quality of life, Android, Multimedia, Medicine, Attention, Brain, Multiple sclerosis, Time management, World government, Patient, Research, FDA, Dietary supplement, Toy, Nursing, Yolo Akili

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today released EndeavorOTCTM, a new immersive mobile video game treatment that is clinically proven to improve attention and focus, specifically in adults with ADHD.

Key Points: 
  • Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today released EndeavorOTCTM, a new immersive mobile video game treatment that is clinically proven to improve attention and focus, specifically in adults with ADHD.
  • EndeavorOTC is built on the same technology as Akili’s EndeavorRxⓇ, the world’s first and only FDA-authorized video game treatment now being prescribed for children 8-12 years old with ADHD.
  • "New, easily accessible treatments are needed to effectively support adults with ADHD,” said Duane Gordon, President, Attention Deficit Disorder Association (ADDA).
  • “I’m delighted to see new technology used to develop a unique approach to treatment, and a video game treatment is a fun and engaging way to empower adults with ADHD."